Literature DB >> 31669403

Setup Management for Stereotactic Body Radiation Therapy of Patients With Pancreatic Cancer Treated via the Breath-Hold Technique.

Roland Forbang Teboh1, Senthamizhchelvan Srinivasan2, Sweet Ping Ng3, Maureen L Aliru3, Joseph M Herman4.   

Abstract

PURPOSE: Active Breathing Coordinator (Elekta AB, Crawley, UK) is a motion management strategy for radiation treatment. During setup, aligning the patient to the bony spine alone does not necessarily lead to an accurate alignment to soft tissue targets, and further adjustment is necessary. Determining a safe range of values for such adjustments is an important quality assurance measure and was the purpose of this study, with focus on stereotactic body radiation therapy in patients with pancreatic cancer. METHODS AND MATERIALS: The retrospective study included 19 previously treated patients. For each fraction, a free-breathing cone beam computed tomography scan was registered to a reference breath-hold computed tomography for alignment to the spine. Two perpendicular breath-hold kV projection images were then acquired and compared with corresponding reference digitally reconstructed radiographs for additional alignment with a surrogate fiducial marker. By comparing the breath-hold kV projection images from subsequent treatment fractions with those from the first fraction, we derived the 3-dimensional variability of the fiducial position with respect to the reference image.
RESULTS: We observed intrafraction setup error to be within 2.0 mm. For interfraction, we observed average reproducibility of 1.7 ± 0.8 mm, 2.0 ± 1.4 mm, and 3.2 ± 2.5 mm in the left-right (LR), anterior-posterior (AP), and superior-inferior (SI) directions, respectively. The average excursion values from free breathing spine to breath-hold fiducial alignment were 1.5 ± 1.4 mm, 2.0 ± 1.9 mm, and 3.0 ± 2.0 mm in the LR, AP and SI directions, respectively. The observed ranges of average excursions among all patients were 0.2 to 5.1 mm, 0.1 to 5. 9 mm, and 0.6 to 7.8 mm in the LR, AP, and SI directions, respectively.
CONCLUSIONS: This study demonstrates that intrafraction targeting errors can be within 2 mm, and interfraction shifts from free-breathing spine to Active Breathing Coordinator breath-hold target can be as high as 8 mm. Values that deviate significantly would need further investigation to rule out factors such as local progression, bowel gas, or fiducial shift before treatment.
Copyright © 2019 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31669403     DOI: 10.1016/j.prro.2019.10.012

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  5 in total

1.  Dosimetric feasibility on hypofractionated intensity-modulated radiotherapy and simultaneous integrated boost for locally advanced unresectable pancreatic cancer with helical tomotherapy.

Authors:  Feng Teng; Lingling Meng; Fuhai Zhu; Gang Ren
Journal:  J Gastrointest Oncol       Date:  2021-04

2.  Geometric Reproducibility of Fiducial Markers and Efficacy of a Patient-Specific Margin Design Using Deep Inspiration Breath Hold for Stereotactic Body Radiation Therapy for Pancreatic Cancer.

Authors:  Sarah Han-Oh; Colin Hill; Ken Kang-Hsin Wang; Kai Ding; Jean L Wright; Sara Alcorn; Jeffrey Meyer; Joseph Herman; Amol Narang
Journal:  Adv Radiat Oncol       Date:  2021-01-22

3.  Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar.

Authors:  Renzo Mazzarotto; Nicola Simoni; Stefania Guariglia; Gabriella Rossi; Renato Micera; Riccardo De Robertis; Alessio Pierelli; Emanuele Zivelonghi; Giuseppe Malleo; Salvatore Paiella; Roberto Salvia; Carlo Cavedon; Michele Milella; Claudio Bassi
Journal:  Front Oncol       Date:  2020-12-17       Impact factor: 6.244

4.  Fiducial-based image-guided SBRT for pancreatic adenocarcinoma: Does inter-and intra-fraction treatment variation warrant adaptive therapy?

Authors:  Colin S Hill; Sarah Han-Oh; Zhi Cheng; Ken Kang-Hsin Wang; Jeffrey J Meyer; Joseph M Herman; Amol K Narang
Journal:  Radiat Oncol       Date:  2021-03-19       Impact factor: 3.481

5.  KIF23 enhances cell proliferation in pancreatic ductal adenocarcinoma and is a potent therapeutic target.

Authors:  Chun-Tao Gao; Jin Ren; Jie Yu; Sheng-Nan Li; Xiao-Fan Guo; Yi-Zhang Zhou
Journal:  Ann Transl Med       Date:  2020-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.